[ad_1]
NEW YORK , July 6, 2022 /PRNewswire/ –The anti-obesity drugs market will be driven by factors such as the growing obese population. Diseases such as obesity, cardiovascular diseases, stroke, diabetes, and atherosclerosis are caused by factors such as sedentary lifestyle and lack of a balanced diet. The prevalence of obesity has increased significantly all over the world. Obesity also has a significant impact on cancer rates . Therefore, the global increase in the prevalence of obesity offers significant opportunities for drug manufacturing companies to make innovative and highly effective drugs during the forecast period.
The “Anti-obesity Drugs Market by Type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs) and Geography (North America, Europe, Asiaand ROW) – Forecast and Analysis 2021-2025” report has been added to Technavio’s offering. The potential growth difference for the anti-obesity drugs market between 2020 and 2025 is USD 454.51mn.
The availability of anti-obesity devices will challenge the global anti-obesity drugs market. Various physical activities and weight loss supplements are considered preventive measures for obesity. Apart from this, there are obesity treatment devices such as gastric band and electrical stimulation system. These devices are highly preferred owing to their fast results. Thus, many obese people prefer to undergo these treatments instead of taking drugs. Therefore, the growing adoption of anti-obesity devices is a major challenge for the growth of the global anti-obesity drug market.
The anti-obesity drugs market report is segmented by type (class III anti-obesity drugs, class II anti-obesity drugs, and class I anti-obesity drugs) and geography (North America, Europe, Asiaand ROW).
By type, the class III anti-obesity drugs segment will have significant market share growth during the forecast period. Most of the drugs offered in the market are targeted at patients who are categorized under class III. Moreover, the rise in R&D by manufacturers for new anti-obesity drugs may boost the growth of the global class III anti-obesity drugs market during the forecast period.
By geography, North America will be the leading region with 71% of the market’s growth during the forecast period. The US and Canada are the key countries for the anti-obesity drugs market in the region. The presence of a large obese …
Full story available on Benzinga.com
[ad_2]
Source link
